Xenon Pharmaceuticals (XENE) Non-Current Debt (2017 - 2019)

Historic Non-Current Debt for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q1 2020 value amounting to $15.7 million.

  • Xenon Pharmaceuticals' Non-Current Debt rose 354.71% to $15.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $15.7 million, marking a year-over-year increase of 354.71%. This contributed to the annual value of $10.9 million for FY2019, which is N/A changed from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Non-Current Debt of $15.7 million as of Q1 2020, which was up 354.71% from $10.9 million recorded in Q4 2019.
  • In the past 5 years, Xenon Pharmaceuticals' Non-Current Debt ranged from a high of $15.7 million in Q1 2020 and a low of $5.5 million during Q1 2018
  • Over the past 4 years, Xenon Pharmaceuticals' median Non-Current Debt value was $11.8 million (recorded in 2019), while the average stood at $11.7 million.
  • Over the last 5 years, Xenon Pharmaceuticals' Non-Current Debt had its largest YoY gain of 17646.09% in 2019, and its largest YoY loss of 2082.49% in 2019.
  • Xenon Pharmaceuticals' Non-Current Debt (Quarter) stood at $6.1 million in 2017, then soared by 143.87% to $14.9 million in 2018, then dropped by 26.85% to $10.9 million in 2019, then skyrocketed by 43.96% to $15.7 million in 2020.
  • Its Non-Current Debt stands at $15.7 million for Q1 2020, versus $10.9 million for Q4 2019 and $11.8 million for Q3 2019.